Institute for International Research

TIDES® Scientific Advisory Board

• Bob D. Brown, Ph.D., Vice President, Research and Technology, Genta, Inc.
• Masad J. Damha, Ph.D., F.C.I.C., James McGill Professor of Chemistry, McGill University, Canada
• Mark E. Davis, Ph.D., Warren and Katharine Schlinger Professor of Chemical Engineering, California Institute of Technology
• Christopher P. Holmes, Ph.D., Senior Director, Chemistry, Affymax, Inc.
• Aimee Jackson, Ph.D., Senior Research Fellow, Rosetta Inpharmatics, LLC
• Tim Lannan, Senior Manager, Global Manufacturing Services, Pfizer Inc
• John P. Mayer, Ph.D., Senior Research Advisor, Eli Lilly and Co.
• Paul McCormac, Ph.D., Director, Process and Analytical Development, Avecia OligoMedicines
• Mauri Okamoto-Kearny, MS Biochemistry, MBA Finance, Vice President, Product Development and New Product Planning, KAI Pharmaceuticals, Inc.
• James Powell, General Manager, Agilent Technologies
• Christopher A. Rhodes, Ph.D., Executive Director, Pharmaceutical Sciences, Amylin Pharmaceuticals, Inc.
• Martin Robitaille, Ph.D., Associate Director Peptide Chemistry, ConjuChem Biotechnologies Inc., Canada
• Jane Salik, President, PolyPeptide Laboratories, Inc.
• Anthony N. Scozzari, Vice President, Development Chemistry, Isis Pharmaceuticals, Inc.
• G. Susan Srivatsa, Ph.D., President, ElixinPharma
• Aleksander Swietlow, Ph.D., Principal Scientist, Pharmaceutics, Amgen Inc.
• James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, Quark Pharmaceuticals, Inc.
• Fran Wincott, Ph.D., President, Wincott & Associates, LLC

TIDES® Distinguished Faculty

• K.A. Ajit-Simh, President, Shiba Associates
• Firoz D. Antia, Ph.D., Executive Director Chemical & Analytical Development, Palatin Technologies, Inc.
• Dr. Hüseyin Aygün, Chief Scientific Officer, BioSpring GmbH, Germany
• Brenda F. Baker, Ph.D., Director, Clinical Development, Isis Pharmaceuticals, Inc.
• James Blackwell, Ph.D., Senior Consultant, BioProcess Technology Consultants, Inc.
• Jason Bock, Ph.D., Senior Manager, Pharmaceutical Development, CoGenesys
• Marie-Hélène Brichard, Ph.D., Head of Process Development, Lonza Braine, Belgium
• Bob D. Brown, Ph.D., Vice President, Research and Technology, Genta Incorporated
• Paul A. Burke, Ph.D., Principal, Drug Delivery Consulting, LLC; Consultant, former Executive Director, Pharmaceutics, Amgen Inc.
• John Burt, Ph.D., Chief Executive Officer, Thiakis Limited, United Kingdom
• Daniel Capaldi, Ph.D., Executive Director, Development Chemistry, Isis Pharmaceuticals, Inc.
• Sandra Carriero, Ph.D., Senior Research Scientist/Manager, Immunochemistry, Laboratory Sciences, Charles River Laboratories, Preclinical Services Montreal Inc., Canada
• Steven M. Chamow, Ph.D., Senior Vice President, CMC, Intradigm Corporation
• Rick E. Cooley, Manager, Process Analytics Center of Excellence, Dionex Corporation; Eli Lilly and Company (retired)
• Masad J. Damha, Ph.D., F.C.I.C., James McGill Professor of Chemistry, McGill University, Canada
• Waleed Danho, Ph.D., Distinguished Research Leader, Discovery Chemistry, Hoffmann-LaRoche Inc.
• Mark E. Davis, Ph.D., Warren and Katharine Schlinger Professor of Chemical Engineering, California Institute of Technology
• Seppe De Gelas, Head of Quality Assurance and Regulatory Affairs, Lonza Braine, Belgium
• Andrew Dibble, Ph.D., Associate Director, Pharmaceutical Development, Isis Pharmaceuticals, Inc.
• Thomas A. Dix, Ph.D., Co-Founder and CSO, Argolyn Bioscience Inc.
• Andrew D. Ellington, Ph.D., Wilson and Kathryn Fraser Research Professor in Biochemistry, The University of Texas at Austin; Co-Founder, b3 bio, Inc.
• Shai Erlich, Ph.D., Chief Development Officer, Quark Pharmaceuticals, Inc.
• Christine Esau, Ph.D., Project Leader, microRNA Biology, Regulus Therapeutics
• Kevin Fettes, Ph.D., Process Development Group Leader, Avecia OligoMedicines
• Mark Fineman, Executive Director, Clinical Pharmacology, Amylin Pharmaceuticals, Inc.
• Blair A. Fraser, Ph.D., Director, Division of Pre-Marketing Assessment I, Office of New Drug Quality Assessment, Office of Pharmaceutical Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
• Hans Gaus, Ph.D., Director, Structural Biology, Isis Pharmaceuticals, Inc.
• Mark J. Ginski Ph.D., Director Product and Analytical Development, Alba Therapeutics Corporation
• Larry Gold, Ph.D., CEO and Chairman, SomaLogic, Inc.
• Neil I. Goldstein, Ph.D., President, Antyra Inc.
• Paul J. Hatala, Ph.D., Principal Investigator/CMC, Archemix Corp.
• Jeremy Heidel, Ph.D., Chief Scientific Officer, Calando Pharmaceuticals
• Kenneth W. Hill, Ph.D., Director, Process Development, Agilent Technologies, Inc
• Michael S. Holfinger, Ph.D., Director, API Manufacturing and Process Development, Affymax, Inc.
• Christopher P. Holmes, Ph.D., Senior Director, Chemistry, Affymax, Inc.
• Massimo Iacobelli, M.D., Senior Vice President and Scientific Director, Gentium S.p.A., Italy
• Patrick Iversen, Ph.D., Senior Vice President, Research & Development, AVI Biopharma
• Aimee Jackson, Ph.D., Senior Research Fellow, Molecular Profiling, Rosetta Inpharmatics, LLC., a wholly-owned subsidiary of Merck & Co., Inc.
• Alex Kanarek, Ph.D., Quality Consultant, BioProcess Technology Consultants, Inc.
• Troels Koch, Ph.D., Vice President, Research, Santaris Pharma A/S, Denmark
• Mark J. Krantz, Ph.D., Vice President, Scientific Affairs, BioMS Medical Corp., Canada
• Todd Kreutzian, Director, Analytical Development, Agilent Technologies
• Arthur M. Krieg, M.D., Chief Scientific Officer and Executive Vice President of R&D, Coley Pharmaceutical Group, Inc.
• Gopal Krishna, Ph.D., Senior Director Technical Operations, The Medicines Company
• Tim Lannan, Senior Manager, Global Manufacturing Services, Pfizer Inc
• Derek Maclean, Ph.D., Director, Chemistry, KAI Pharmaceuticals, Inc.
• Muthiah Manoharan, Ph.D., Vice President, Drug Discovery, Alnylam Pharmaceuticals
• James D. Marks, M.D., Ph.D., Department of Anesthesia and Pharmaceutical Chemistry, Member, Comprehensive Cancer Center, University of California, San Francisco
• William S. Marshall, PhD., President and Chief Executive Officer, Miragen Therapeutics
• John P. Mayer, Ph.D., Senior Research Advisor, Eli Lilly and Co.
• James V. McArdle, Ph.D., Vice President, Chemistry, Manufacturing and Controls, Archemix Corporation
• Paul McCormac, Ph.D., Director, Process and Analytical Development, Avecia OligoMedicines
• Janet M. McNicholas, Ph.D., Partner, Bell, Boyd and Lloyd, LLP
• Nozer Mehta, Ph.D., Vice President, Biological R&D, Unigene Laboratories, Inc.
• Paul Metz, Senior Director, Manufacturing Operations, Agilent Technologies Inc.
• Adam R. Mezo, Ph.D., Associate Director, Chemistry, Syntonix Pharmaceuticals, Inc.
• Roger P. Micheli, Ph.D., Manager, Analytical Research and Regulatory Affairs, Roche Colorado Corporation
• Richard Mitchell, Ph.D., Scientific Director, Marketing and Business Development, Nastech Pharmaceutical Company, Inc.
• Lubomir V. Nechev, Ph.D., Director, Process Chemistry, Alnylam Pharmaceuticals
• John S. Patton, Ph.D., CSO and Founder, Nektar
• Pamela A. Pavco, Ph.D., Vice President, Pharmaceutical Development, RXi Pharmaceuticals Corp.
• James Powell, General Manager, Agilent Technologies
• Claus Rentel, Ph.D., Associate Director, Development Chemistry, Isis Pharmaceuticals, Inc
• Christopher A. Rhodes, Ph.D., Executive Director, Pharmaceutical Sciences, Amylin Pharmaceuticals, Inc.
• Dr. Peter Richardson, MRCP, Corporate Vice President and Chief Scientific Officer, MannKind Corporation
• Ipsita Roymoulik, Ph.D., Senior Analytical Chemist, Quality Control, Avecia Biotechnology
• Christopher P. Rusconi, Ph.D., Chief Scientific Officer, Regado Biosciences, Inc.
• Alan Sachs, M.D., Ph.D., Vice President, RNA Therapeutics, Merck Research Laboratories
• Jane Salik, President, PolyPeptide Laboratories, Inc.
• Alan D. Schreiber, M.D., Manager, ZaBeCor Pharmaceutical Company, LLC
• Claudio D. Schteingart, Ph.D., Senior Director of Chemistry, Ferring Research Institute Inc.
• Adam Schwab, Senior Scientist, Global Manufacturing Services, Pfizer Inc.
• Anthony Scozzari, Vice President, Development Chemistry, Isis Pharmaceuticals, Inc.
• Elisabeth C. Roberts Solano, Ph.D., Associate Director, Project Management, Quark Pharmaceuticals, Inc.
• Riccardo Spizzo, M.D., Senior Research Associate, The University of Texas M.D. Anderson Cancer Center
• G. Susan Srivatsa, Ph.D., President, ElixinPharma
• Chris Steinhardt, Partner, Knobbe Martens Olson and Bear LLP
• Aleksander Swietlow, Ph.D., Principal Scientist, Pharmaceutics, Amgen Inc.
• Michael V. Templin, Ph.D., Director, Pharmacology and Toxicology, Nastech Pharmaceutical Company, Inc.
• Jim Thayer, Ph.D., Staff Research Biochemist, R&D, Dionex Corporation
• James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, Quark Pharmaceuticals, Inc.
• Dr. René Thürmer, Deputy Head Unit Pharmaceutical Biotechnology, BfArM - Federal Institute for Drugs and Medical Devices, Germany
• John C. Tolle, Senior Group Leader, Global Pharmaceutical Products Division Process R&D, Abbott Laboratories
• Michael Verlander, D. Phil., Executive Vice President, PolyPeptide Laboratories, Inc.
• Nicholas Vrolijk, Ph.D., Vice President, Manufacturing Operations, Gloucester Pharmaceuticals, Inc.
• Sarah Walter, Ph.D., Senior Scientist, Molecular Pharmacology, KAI Pharmaceuticals, Inc.
• Richard Warburg, Ph.D., Partner, Foley & Lardner LLP
• Oleg Werbitzky, Ph.D., Head, R&D Peptides and Oligonucleotides, Lonza Valais Works, Switzerland
• Fran Wincott, Ph.D., President, Wincott & Associates, LLC
• Tadeusz K. Wyrzykiewicz, Ph.D., Oligonucleotides Supervisor, Girindus America Inc.
• Qiang Ye, Ph.D., Associate Director, Product Development, Amylin Pharmaceuticals, Inc.
• J. Jim Zhang, Ph.D., Director, Analytical Research and Development, Affymax, Inc.

Nucleic Acids Technologies for Diagnostics

Scientific Advisory Board

• Michael Christopherson, Ph.D., Group Leader, Oligonucleotide Manufacturing, Roche Molecular Systems, Inc.
• B. Melina Cimler, Ph.D., Vice President, Regulatory Affairs, Beckman-Coulter Inc.
• Loren "Dick" Keys, Ph.D., Senior Director, Chemistry and Product Development, Osmetech Molecular Diagnostics, Inc.
• Marc Lemaitre, Ph.D., Director, R&D, Glen Research Corp.
• Timothy Stenzel, M.D., Ph.D., Senior Director, Medical, Regulatory and Clinical Affairs, Abbott Molecular
• Diane Wolfe, Vice President, Manufacturing, Celera

Distinguished Faculty

• B. Melina Cimler, Ph.D., Vice President, Regulatory Affairs, Beckman-Coulter Inc.
• William Cork, Vice President of R&D, Chief Technology Officer, Nanosphere
• Jim Darnell, Manager, Life Sciences, Clarkson Consulting
• Brian DuChateau, Ph.D., Vice President, Laboratory Operations, Converge Diagnostic Services
• Michael D. Geier Ph.D., Director, Analytical Development and Test Method Validation, Roche Molecular Diagnostics
• Andrew Grupe, Ph.D., Senior Director, Pharmacogenomics and Director, CNS Research, Celera
• Steven I. Gutman, M.D., Director, Office of In Vitro Diagnostic Device Evaluation and Safety, CDRH, U.S. Food and Drug Administration
• Peter Haima, Ph.D., Senior Project Manager In Vitro Diagnostics, Eurogentec S.A., Belgium
• Lori K. Hennessy, Ph.D., Director, R&D, Human Identification Group, Applied Markets Division, Applied Biosystems
• Ichiro Hirao, Ph.D., Team Leader, Nucleic Acid Synthetic Biology Research Team, RIKEN Genomic Sciences Center (GSC); President, TagCyx Biotechnologies, Japan
• Stuart Hogarth, Visiting Research Fellow, Institute for Science and Society, Nottingham University, United Kingdom
• Petra Kaars-Wiele, Ph.D., Senior Director, International Regulatory Affairs and Affiliate Compliance, Diagnostic Division, Abbott Laboratories, Germany
• Dick Keys, Ph.D., Senior Director, Chemistry and Product Development, Osmetech Molecular Diagnostics
• Gary J. Latham, Ph.D., Head of Technology Development, Asuragen, Inc.
• Marc Lemaitre, Ph.D., Director, R&D, Glen Research Corp.
• Glenn A. Miller, Ph.D., Vice President, General Manager, Genzyme Analytical Services
• William J. Pignato, Senior Scientist, Regulatory Affairs, Genentech, Inc.
• Tamara Ranalli, Ph.D., Manager, Business Development and Quality Systems, BioHelix Corporation
• E. Ralf Schönbrunner, Ph.D., Vice President, Research and Development, AcroMetrix
• Michele M. Schoonmaker, Ph.D., Director, Government Affairs, Cepheid
• Keld Sorensen, Ph.D., Director, R&D Bioscience Group, Luminex
• Timothy Stenzel, M.D., Ph.D., Vice President, Diagnostics R&D and Chief Medical Officer, Asuragen, Inc., A Spin-Off of Ambion
• Bertrand Tavitian, M.D., Ph.D., Head of the Laboratoire d'Imagerie Moleculaire Experimentale, Institute for Biomedical Imaging, CEA, France
• Monte Wetzel, Ph.D., Director of Licensing, Roche Molecular Systems, Inc.